DAIDS Regulatory Support Center Logo Secure DAIDS RCC Document Collaboration Site Web Site Feedback
Home | About the RSC | Frequently Asked Questions | Contact Information | Useful Links | Web Site Update Log
Broadcast Memos
DAIDS RSC Presentations
Regulatory Information
Protocol Development Information
Human Subjects Protection (HSP)
Protocol Registration
Safety and Pharmacovigilance
Case Report Form
(CRF) Management
Clinical Study
Information Office
Frequently Asked Questions

⊲ Return to Frequently Asked Questions Subject List.

Regulatory

  1. How can I obtain information on the National Clinical Trial (NCT) # ?
  2. Our Institutional Review Board (IRB) requests a letter from the sponsor or the FDA with the IND # for initial application submission. 
ClinicalTrials.gov and FDAAA (Food and Drug Administration Amendments Act)
  1. How do I know who the responsible party is for submitting information to ClincialTrials.gov?
  2. What is an applicable clinical trial?
  3. How do I know whether my trial needs to be registered with ClinicalTrials.gov or whether it needs to be registered AND requires basic results reporting to ClinicalTrials.gov?
  4. How do I know if my new protocol will require the FDAAA mandated informed consent language.
  5. Can I modify the FDAAA mandated informed consent language?
  6. Where can I find information on FDAAA?

∧ Return to Top

General Information

1. How can I obtain information on the National Clinical Trial (NCT) # ?

Please check the ClinicalTrials.gov website first.  If the NCT # is not available, contact the DAIDS RSC at regulatory@tech-res.com.  The DAIDS RSC will forward your request to the DAIDS ClinicalTrials.gov Point of Contact and a response will be provided by either group. 

2. Our Institutional Review Board (IRB) requests a letter from the sponsor or the FDA with the IND # for initial application submission.  How can I obtain this? 

Please send the request to regulatory@tech-res.com and provide the following information: Name and Address of Requestor and Site #.

∧ Return to Top

ClinicalTrials.gov and FDAAA (Food and Drug Administration Amendments Act)

3. How do I know who the responsible party is for submitting information to ClincialTrials.gov?

If the applicable clinical trial involves an IND/IDE, the IND holder would generally be considered the sponsor and the responsible party under FDAAA. i.e. If DAIDS is the IND holder for a study, DAIDS would be the responsible party.

If the applicable clinical trial does not involve an IND/IDE, the grantee institution would generally be considered the sponsor and the responsible party under FDAAA. The grantee institution has the option to designate the PI of the trial as the responsible party. i.e. If it is a Non-IND DAIDS study, the Network or Organization is the responsible party.

For more information, visit http://grants.nih.gov/ClinicalTrials_fdaaa/Responsible_Party.htm.

4. What is an applicable clinical trial?

For an easy flow chart to determine if your trial is an applicable clinical trial under FDAAA, please visit: http://grants.nih.gov/ClinicalTrials_fdaaa/ACTs_under_FDAAA.htm

For a complete definition and description of “applicable clinical trial”, please see http://prsinfo.clinicaltrials.gov/fdaaa.html.

5. How do I know whether my trial needs to be registered with ClinicalTrials.gov or whether it needs to be registered AND requires basic results reporting to ClinicalTrials.gov?

FDAAA requires registration and basic results posting of applicable clinical trials.

If your study does not fall under the requirements for an applicable clinical trial, it may still need to be registered to meet journal publication requirements. The International Committee for Medical Journal Editors (ICMJE) requires only registration of interventional trials http://www.icmje.org/faq_clinical.html.

6. How do I know if my new protocol will require the FDAAA mandated informed consent language?

For trials initiated on or after March 7, 2012, FDAAA requires the mandatory language to be included in informed consents for applicable clinical trials only.

Revisions for existing protocols (e.g. LOAs, Amendments) approved prior to March 7, 2012 do not require the mandatory informed consent language.

For more information on DAIDS implementation of this, please visit: DAIDS Implementation of the New FDA Final Ruling for Mandatory Language Regarding Clinicaltrials.gov for Informed Consents

7. Can I modify the FDAAA mandated informed consent language?

No, the language cannot be modified.
8. Where can I find information on FDAAA?

Full text of FDAAA can be found at: http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=110_cong_public_laws&docid=f:publ085.110

OR

http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=110_cong_public_laws&docid=f:publ085.110.pdf.


 

Document Title Search

Search Help
RSC Quick Contacts
Package Inserts
Investigator Brochures
Website Change Form
 
Latest News & Updates